Technology | May 26, 2011

Devicor to Acquire Neoprobe's Gamma Detection Devices

May 26, 2011 -- Devicor Medical Products Inc., announced it has signed an asset purchase agreement with Neoprobe Corporation to acquire the Neoprobe GDS portfolio of products. Devicor currently provides distribution and marketing services to Neoprobe for the gamma detection systems covered by this agreement.

Financial terms of the agreement include $30 million cash at close, plus up to an additional $20 million in royalties based on revenue milestones. The sale is subject to approval by Neoprobe's shareholders and is expected to close shortly after the shareholders' meeting in August. Neoprobe Corp. markets its gamma detection systems, detector probes and accessories worldwide for surgical procedures called intraoperative lymphatic mapping (ILM) or sentinel lymph node biopsy, a minimally invasive technique for evaluating the potential spread of cancer to lymph node tissues and organs.

Several large-scale national and international studies have evaluated the survival advantage of ILM staging in patients with melanoma and breast cancer. Evaluation of outcomes is ongoing. Neoprobe is also exploring other potential applications for the use of its gamma detection devices in cancer surgery. Neoprobe is the only company developing both gamma detection systems and radiotracers. This combination of technologies represents a first in the health care field and offers a unique ability to optimize the radio tracers and gamma detection system.

The acquisition of the Neoprobe GDS line comes less than a year after Devicor's acquisition of Ethicon Endo-Surgery's (EES) breast care business, Mammotome, which sells products designed to help doctors detect and diagnose breast cancer. GTCR will be investing additional equity capital in Devicor to finance a portion of the purchase price of the Neoprobe GDS assets.

The Mammotome product portfolio is sold in 50 countries around the world and includes the Mammotome Breast Biopsy System as well as tissue markers for breast disease diagnostic sampling and management. Mammotome has distributed and marketed Neoprobe's line of gamma detection systems since 2000, as part of EES and then continuing as part of Devicor.

For more information: www.devicormedical.com, www.mammotome.com

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Breast imaging technologies have seen a rapid evolution.

Breast imaging technologies have seen a rapid evolution.

Feature | Women's Health | June 05, 2018 | By Jeff Zagoudis
Breast imaging technologies have evolved rapidly in the last two decades to help physicians detect breast cancers at
Breast Cancer Survivors Not Getting Recommended Number of Mammograms Post-Surgery
News | Mammography | May 24, 2018
Breast cancer survivors are not getting the recommended level of screening post-surgery, according to a newly-published...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Overlay Init